文献速递白血病

2022年欧洲白血病网遗传风险分类对成人急性髓系白血病结局的预测:一项Alliance研究

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.
PubMed 文献 · Leukemia · 2023-02-23

研究按2022与2017年欧洲白血病网(ELN)遗传风险分类,对1637例接受阿糖胞苷/蒽环类方案治疗的成人急性髓系白血病(AML)患者进行分层。2022版 favorable 组由40%降至35%、adverse 组由37%升至41%;两版分类预测能力相似。2022版在全部患者及<60岁患者中似能准确反映结局,但≥60岁患者中间危与 adverse 组的复发率、无病生存(DFS)和总生存(OS)无显著差异。

要点

  • 2022版ELN分类将 favorable 组由40%降至35%、adverse 组由37%升至41%(对比2017版)。
  • ≥60岁患者中 intermediate 与 adverse 组的复发率、DFS和OS无显著差异。
  • favorable 组中骨髓增生异常相关突变不影响 CEBPAbZIP 突变或核心结合因子AML,但使 NPM1 突变/FLT3-ITD 阴性患者改归 intermediate。

核心结论

  • 2022与2017版ELN分类的结局预测能力相似;分析既证实也质疑部分新增标志物的预后意义。

研究设计与样本

  • 按2022与2017年ELN遗传风险分类,对1637例接受阿糖胞苷/蒽环类方案治疗的成人AML患者进行归类分析。

主要发现

  • 2022版较2017版 favorable 组由40%降至35%、adverse 组由37%升至41%。
  • 2022版遗传风险分组似能准确反映全部患者及<60岁患者的治疗结局。
  • ≥60岁患者中 intermediate 与 adverse 组的复发率、DFS和OS无显著差异。
  • 年轻非裔美国患者中 intermediate 与 adverse 组的DFS和OS无差异,favorable 与 intermediate 组的DFS亦无差异。
  • 西班牙裔患者中 favorable 与 intermediate 组的DFS和OS无差异。

关键数值与推荐

  • favorable 组中骨髓增生异常相关突变不影响 CEBPAbZIP 突变或核心结合因子AML患者,但使 NPM1 突变/FLT3-ITD 阴性患者改归 intermediate。
  • NPM1 突变伴 adverse 风险细胞遗传学异常的患者预后更接近 intermediate 组而非 adverse 组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recently, the European LeukemiaNet (ELN) revised its genetic-risk classification of acute myeloid leukemia (AML). We categorized 1637 adults with AML treated with cytarabine/anthracycline regimens according to the 2022 and 2017 ELN classifications. Compared with the 2017 ELN classification, 2022 favorable group decreased from 40% to 35% and adverse group increased from 37% to 41% of patients. The 2022 genetic-risk groups seemed to accurately reflect treatment outcomes in all patients and patients aged <60 years, but in patients aged ≥60 years, relapse rates, disease-free (DFS) and overall (OS) survival were not significantly different between intermediate and adverse groups. In younger African-American patients, DFS and OS did not differ between intermediate-risk and adverse-risk patients nor did DFS between favorable and intermediate groups. In Hispanic patients, DFS and OS did not differ between favorable and intermediate groups. Outcome prediction abilities of 2022 and 2017 ELN classifications were similar. Among favorable-risk patients, myelodysplasia-related mutations did not affect patients with CEBPAbZIP mutations or core-binding factor AML, but changed risk assignment of NPM1-mutated/FLT3-ITD-negative patients to intermediate. NPM1-mutated patients with adverse-risk cytogenetic abnormalities were closer prognostically to the intermediate than adverse group. Our analyses both confirm and challenge prognostic significance of some of the newly added markers.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Mrózek K, Kohlschmidt J, Blachly JS, et al. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 2023. PMID: 36823396. doi:10.1038/s41375-023-01846-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。